Description: AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.
Home Page: www.aptabio.com
Tower 504, 13
Yongin-si,
16954
South Korea
Phone:
82 70 7152 0097
Officers
| Name | Title |
|---|---|
| Dr. Jin Lee Soo | Chief Exec. Officer |
| Dr. Hwan Moon Sung | Pres & CSO |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 926.1378 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |